HPV16 E7 (86-93) (TFA)
目录号 : GC61544
HPV16E7(86-93)TFA是人类白细胞抗原(HLA)-A2.1限制的HPV16E7衍生肽。HPV16E7(86-93)TFA在宫颈癌中具有免疫原性。
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas[1][2].
HPV16 E7 (86-93) specific T cells are expandable upon IVS (in vitro stimulation) with cognate peptide-pulsed dendritic cells (DCs) and are reactive against peptide-pulsed targets or, in case of the E711-20 epitope-specific T cells, against HPV16 E7 expressing CaSki cell line[1]. For peptide HPV16 E7 (86-93), the only response against K562 cells pulsed with the corresponding peptide was significantly blocked by anti-HLA class I Ab w6/32, which was not the case for HPV16 E7 expressing tumor cell line CaSki. Precursor T cells specific for HPV16 E7 (86-93) peptide is able to differentiate, at least in vitro, into HPVspecific effector cells[1].HPV16 E7 peptide-loaded autologous dendritic cells (DCs) are able to stimulate a specific cytotoxic CD8+ T-cell response[2].
HPV16 E7 (86-93) peptide in IVS culture has specific T cell expansion. The HPV16 E7 (86-93) specific T cells produced does not recognize naturally HPV16 E7 expressing cell line CaSki. HPV16 E7 (86-93) peptides also has similar observations in transgenic mice. The HPV16 E7 (86-93) peptide is able to induce cytotoxic T lymphocyte (CTL) responses if loaded on the antigen presenting HLA class I molecules, but that the peptide appears not to be processed or presented by HPV16 infected cells[1].
[1]. Hoffmann TK, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer. 2006 Apr 15;118(8):1984-91. [2]. Cheng WF, et al. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology. 2005 May;115(1):136-49.
| Cas No. | SDF | ||
| 分子式 | C39H67F3N8O12S | 分子量 | 929.06 |
| 溶解度 | DMSO: 100 mg/mL (107.64 mM); Water: 6.67 mg/mL (7.18 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.0764 mL | 5.3818 mL | 10.7636 mL |
| 5 mM | 0.2153 mL | 1.0764 mL | 2.1527 mL |
| 10 mM | 0.1076 mL | 0.5382 mL | 1.0764 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet